Stanley S. Scott Cancer Center Speaker Series

aboutlcrc

Stanley S. Scott Cancer Center Invited Speaker Series

(Supported by the Louisiana Cancer Research Consortium)
(Sponsored CME series)

Time & Location:

1st & 3rd Thursday at Noon
Louisiana Cancer Research Center
1700 Tulane Ave., 1st Floor Conference Room
(unless otherwise noted)

Statement of Need: The purpose of the Stanley S. Scott Cancer Center (SSSCC) Invited Speaker Series is to fulfill an educational need in the local community by providing the latest research and findings in the field of oncology. In this capacity the series serves to build upon the competencies of those in attendance as a resource for information on research and treatment protocols. Communication among physicians and researchers to share their experiences in clinical and laboratory settings is encouraged to foster an atmosphere of collaboration. Presentations and discussion of current topics helps to keep audience members informed on the latest research and developments in cancer diagnosis and treatment.

Target Audience: The target audience for this activity includes oncologists, hematologists, nurses, techs, medical students, and health care providers with an interest in cancer treatment and research.

Objectives: After participating in this educational activity, the attendee should be better able to:

  1. Effectively communicate the nature and scope of a wide range of problems potentially facing cancer patients with those at all levels of cancer research and treatment
  2. Apply the latest scientific research into daily practice of managing patients with oncologic conditions
  3. Collaborate with others in the field of cancer research and treatment in order to maximize available resources for the treatment of cancer patients
  4. Institute new diagnostic and treatment strategies to improve overall healthcare for cancer patients

Accreditation/Designation of Credit: LSU School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

LSU School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

LSU School of Medicine presents this activity for educational purposes only and does not endorse any product, content of presentation or exhibit. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected because of their recognized expertise.

Facilitated by: The LSU Health Sciences Center – Institute of Professional Education

Faculty Disclosure: It is the policy of Continuing Education at LSU School of Medicine to plan and implement all of its educational activities in accordance with the ACCME’s Essential Areas and Policies to ensure balance, independence, objectivity and scientific rigor. In accordance with the ACCME’s 2004 Standards for Commercial Support, everyone who is in a position to control the content of an educational activity certified for AMA PRA Category 1 Credit™ is required to disclose all relevant financial relationships with any commercial interests within the past 12 months that creates a real or apparent conflict of interest. Individuals who do not disclose are disqualified from participating in a CME activity. Individuals with potential for influence or control of CME content include planners and planning committee members, authors, teachers, educational activity directors, educational partners, and others who participate, e.g. facilitators and moderators. This disclosure pertains to relationships with pharmaceutical companies, biomedical device manufacturers or other corporations whose products or services are related to the subject matter of the presentation topic. Any real or apparent conflicts of interest related to the content of the presentations must be resolved prior to the educational activity. Disclosure of off-label, experimental or investigational drugs or devices must also be made known to the audience.


Speaker Schedule for 2017

Date Speaker Title
January 19 J. Silvio Gutkind, Ph.D.
Professor, Department of Pharmacology
UC San Diego Moores Cancer Center
La Jolla, CA
(TBD)
February 2 Kathleen Schmeler, M.D.
Associate Professor
Department of Gynecologic Oncology
University of Texas MD Anderson Cancer Center
Houston, TX
(TBD)
February 16
Michael Shurin, M.D., Ph.D.
Associate Professor of Pathology
University of Pittsburgh Medical Center
Pittsburgh, PA
“Neuroglia as a New Player in the Tumor Immunoenvironment”
March 16 Murray Korc, M.D.
Professor of Medicine, Biochemistry, and Molecular Biology
Indiana University School of Medicine
Indianapolis, IN
(TBD)
April 6
Eduardo Davila, Ph.D.
Associate Professor of Microbiology and Immunology
University of Maryland School of Medicine
Baltimore, MD
(TBD)
May 4 Xiaoqi Liu, Ph.D.
Professor of Biochemistry
Perdue University
West Lafayette, IN
(TBD)
May 18 Sudhir Srivastava, Ph.D., MPH
Chief, Early Detection Research Network (EDRN)
NCI, NIH
Bethesda, MD
(TBD)


Speaker Schedule for 2016

Date Speaker Title
January 14 Rakesh K. Srivastava, Ph.D.
Professor and Senior Scientist
Division of Pharmacology
University of Missouri
Kansas City, MO
“Cancer Stem Cells – A Big Challenge For the Future”
January 21
Ram Samudrala, Ph.D.
Professor and Chief, Division of Bioinformatics
The State University of New York
Buffalo, NY
“Interactomics: Computational Analysis of Novel Drug Opportunities”
February 12 Eva Szabo, M.D.
Chief, Lung and Upper Aerodigestive Cancer Research Group
Division of Cancer Prevention, NCI, NIH
Bethesda, MD
“Early Phase Clinical Development of Cancer Preventive Agents- the NCI Experience”
February 18
José R. Conejo-Garcia, M.D., Ph.D.
Professor and Program Leader, Tumor Microenvironment and Metastasis Program
Wistar Institute
Philadelphia, PA
“Dynamic Expression of the Genomic Organizer Satb1 Governs Dendritic Cell Differentiation and Function in Health and Cancer”
March 3 Protul Shrikant, Ph.D.
Professor of Immunology and Pharmacology
Mayo Clinic
Scottsdale, AZ
“Regulating CD8+ T Cell Fate for Tumor Immunity”
March 10 Victoria Seewaldt, M.D.
Ruth Ziegler Professor and Chair
Department of Population Sciences, City of Hope
Duarte, CA
“Early Detection of Breast Cancer:  From the Bench to the Community and Back”
 April 7
Haidong Dong, M.D., Ph.D.
Associate Professor of Immunology
Mayo Clinic
Rochester, MN
“Two Signaling Pathways of B7-H1 in Regulation of T Cell Responses in Cancers”
April 19 Haojie Huang, Ph.D.
Professor
Department of Biochemistry and Molecular Biology
Mayo Clinic College of Medicine
Rochester, MN
“SPOP:  An Emerging Tumor Suppressor and Therapeutic Marker in Prostate Cancer”
April 20 V. Craig Jordan, Ph.D., D.Sc.
Professor of Breast Medical Oncology
MD Anderson Cancer Center
Houston, TX
“Acquired Resistance to Long-Term Anti-Hormone Adjuvant Therapy:  Demystifying ER Mutations in Metastatic Breast Cancer”
May 19 Scott Abrams, Ph.D.
Professor of Oncology
Department of Immunology
Roswell Park Cancer Institute
Buffalo, NY
“Why ‘Myeloid Health’ is Critically Important for Immune Control of Neoplastic Disease”
June 16 Immaculata De Vivo, Ph.D.
Associate Professor of Epidemiology
Harvard T.H. Chan School of Public Health
Boston, MA
“Genetic and Environmental Risk Factors for Endometrial Cancer:  An Update”
July 7 Tim F. Greten, M.D.
Senior Investigator and Chief, Gastrointestinal Malignancy Section
TGIB, National Cancer Institute
Bethesda, MD
“Immunology and Immunotherapy of Hepatocellular Carcinoma”
September 8
Elvan Daniels, M.D., MPH
Clinical Assistant Professor & Associate Director, Community-Oriented Primary Care
Morehouse School of Medicine
Atlanta, GA
“American Cancer Society Research Funding Opportunities”
September 15 Lawrence Lum, M.D., DSc
Professor of Oncology
Wayne State University
Detroit, MI
“Bispecific Antibody Targeted T cells as Vaccines in Liquid and Solid Tumors”
October 20 Li Ma, Ph.D.
Associate Professor
Department of Experimental Radiation Oncology
MD Anderson Cancer Center
Houston, TX
“Determinants of Tumor Progression, Metastasis, and Therapy Resistance”
November 3 Wael M. ElShamy, Ph.D.
Associate Professor of Radiation Oncology and Pathology
University of Mississippi Medical Center
Jackson, MS
“On the Road to Eliminating Tumor Initiating Cells in Breast Cancers:  Are We There Yet?”
December 15 Robert L. Ferris, M.D., Ph.D.
UPMC Endowed Professor and Chief
Division of Head and Neck Surgery
University of Pittsburgh
Pittsburgh, PA
“Targeting HPV+ H&N Cancer Using Novel Therapeutics – From Robotics to Immunotherapy”
December 16 Rakesh Kumar, Ph.D.
Professor, Department of Biochemistry and Molecular Medicine
George Washington University – Washington, D.C.
“Signal-Dependent Control of Epigenome During Breast Cancer Progression”


For more information, please contact:

Joshua Lovell, B.A.
Phone:  504-210-2829
Email: jlove1@lsuhsc.edu

Academic Co-Coordinators for the Invited Speaker Series:

Lucio Miele, Ph.D.
Phone:  504-210-3433
Email: lmiele@lsuhsc.edu

Jennifer Cameron, Ph.D.
Phone:  504-568-2785
Email: jcame2@lsuhsc.edu